ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 903,29
0,23%
DAX
17 932,17
-1,10%
Brent Oil
83,54
-2,74%
Bitcoin
57 881,66
-4,49%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. FibroGen Inc (FGEN)

  7. FibroGen Inc (FGEN) Actualités

FGEN FibroGen Inc

1,20
0,08 (7,14%)
Après les heures de négociation
Dernière mise à jour : 23:21:51
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
FibroGen Inc FGEN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,08 7,14% 1,20 23:21:51
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,12 1,09 1,2168 1,17 1,12
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/4/202413:00GLOBEFibroGen to Report First Quarter 2024 Financial Results
24/4/202422:02GLOBEFibroGen Announces Clinical Data from Dose Escalation Phase..
02/4/202423:46GLOBEFibroGen Announces Topline Results from Phase 1 Monotherapy..
26/3/202412:00GLOBEFibroGen to Present at 23rd Annual Needham Virtual..
11/3/202412:00GLOBEFibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
09/3/202401:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/3/202401:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/3/202401:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:08EDGAR2Form 8-K - Current report
26/2/202422:06GLOBEFibroGen Reports Fourth Quarter and Full Year 2023 Financial..
26/2/202422:05GLOBEFibroGen Regains All Rights to Roxadustat from AstraZeneca..
24/2/202402:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/2/202402:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/2/202402:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202413:00GLOBEFibroGen to Report Fourth Quarter and Full Year 2023..
14/2/202421:37EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/2/202402:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202413:00GLOBEFibroGen To Host Part I of Virtual KOL Investor Event Series..
25/1/202413:00GLOBEFibroGen Announces Completion of the Pamrevlumab Arm in..
27/12/202301:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/12/202323:02GLOBEFibroGen Presents Data from Phase 3 MATTERHORN Trial of..
06/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202322:05EDGAR2Form 8-K - Current report
06/11/202322:01GLOBEFibroGen Reports Third Quarter 2023 Financial Results
03/11/202321:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/10/202322:30EDGAR2Form 8-K - Current report
23/10/202313:00GLOBEFibroGen to Report Third Quarter 2023 Financial Results
26/9/202301:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202323:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202322:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/9/202322:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202302:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202302:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/9/202314:55EDGAR2Form 8-K - Current report
02/9/202301:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/9/202301:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/9/202323:31EDGAR2Form 144 - Report of proposed sale of securities
29/8/202323:14EDGAR2Form 8-K - Current report
29/8/202322:15GLOBEFibroGen Announces Topline Results from LELANTOS-2, a Phase..
14/8/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202323:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/8/202301:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202322:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/8/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202322:06EDGAR2Form 8-K - Current report
07/8/202322:01GLOBEFibroGen Reports Second Quarter 2023 Financial Results

Dernières Valeurs Consultées

NASDAQ
FGEN
FibroGen
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés